Revolution Medicines initiated with an Outperform at Mizuho

Mizuho analyst Joseph Catanzaro initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $90 price target The firm believes the company’s portfolio of RAS(ON) inhibitors are positioned to play “significant roles” in pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. Daraxonrasib in PDAC alone can drive “meaningful upside” in the shares, the analyst tells investors in a research note. Mizuho believes Revolution’s portfolio could generate $10B in risk-adjusted sales in 2035.